79 related articles for article (PubMed ID: 23467686)
1. Immune escape of AKT overexpressing ovarian cancer cells.
Hahne JC; Meyer SR; Gambaryan S; Walter U; Dietl J; Engel JB; Honig A
Int J Oncol; 2013 May; 42(5):1630-5. PubMed ID: 23467686
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro.
Hahne JC; Honig A; Meyer SR; Gambaryan S; Walter U; Wischhusen J; Häussler SF; Segerer SE; Fujita N; Dietl J; Engel JB
Oncol Rep; 2012 Dec; 28(6):2023-8. PubMed ID: 22992944
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
[TBL] [Abstract][Full Text] [Related]
4. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS-126 in models of ovarian cancer.
Hahne JC; Kurz A; Meyer SR; Dietl J; Engel JB; Honig A
Arch Gynecol Obstet; 2015 Jan; 291(1):131-41. PubMed ID: 25115278
[TBL] [Abstract][Full Text] [Related]
6. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
7. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer].
Qi C; Zhang QH; Li JX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111
[TBL] [Abstract][Full Text] [Related]
8. Platinum-resistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2.
Cohen S; Bruchim I; Graiver D; Evron Z; Oron-Karni V; Pasmanik-Chor M; Eitan R; Bernheim J; Levavi H; Fishman A; Flescher E
J Mol Med (Berl); 2013 Mar; 91(3):357-68. PubMed ID: 23052480
[TBL] [Abstract][Full Text] [Related]
9. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
[TBL] [Abstract][Full Text] [Related]
10. Combined use of cisplatin plus natural killer cells overcomes immunoresistance of cisplatin resistant ovarian cancer.
Choi SH; Jung D; Kim KY; An HJ; Park KS
Biochem Biophys Res Commun; 2021 Jul; 563():40-46. PubMed ID: 34058473
[TBL] [Abstract][Full Text] [Related]
11. Platinum sensitivity of ovarian cancer cells does not influence their ability to induce M2-type macrophage polarization.
Mlynska A; Povilaityte E; Zemleckaite I; Zilionyte K; Strioga M; Krasko J; Dobrovolskiene N; Peng MW; Intaite B; Pasukoniene V
Am J Reprod Immunol; 2018 Sep; 80(3):e12996. PubMed ID: 29904979
[TBL] [Abstract][Full Text] [Related]
12. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
13. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway.
Zou W; Ma X; Hua W; Chen B; Cai G
Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of CD24(+) ovarian cancer cells to anti-cancer drugs and natural killer cells.
Koh J; Lee SB; Park H; Lee HJ; Cho NH; Kim J
Biochem Biophys Res Commun; 2012 Oct; 427(2):373-8. PubMed ID: 22995296
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10.
Varma RR; Hector SM; Clark K; Greco WR; Hawthorn L; Pendyala L
Oncol Rep; 2005 Oct; 14(4):925-32. PubMed ID: 16142353
[TBL] [Abstract][Full Text] [Related]
16. FAU regulates carboplatin resistance in ovarian cancer.
Moss EL; Mourtada-Maarabouni M; Pickard MR; Redman CW; Williams GT
Genes Chromosomes Cancer; 2010 Jan; 49(1):70-7. PubMed ID: 19830698
[TBL] [Abstract][Full Text] [Related]
17. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
18. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
19. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.
Zhang Y; Wang J; Xiang D; Wang D; Xin X
Int J Oncol; 2009 Nov; 35(5):1069-79. PubMed ID: 19787261
[TBL] [Abstract][Full Text] [Related]
20. Salinomycin inhibits Akt/NF-κB and induces apoptosis in cisplatin resistant ovarian cancer cells.
Parajuli B; Lee HG; Kwon SH; Cha SD; Shin SJ; Lee GH; Bae I; Cho CH
Cancer Epidemiol; 2013 Aug; 37(4):512-7. PubMed ID: 23545383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]